Copay help by condition · Cancer and blood cancer · read 2026-11-08
Metastatic Breast Cancer: which charitable copay funds are open
All 3 funds we hold for Metastatic Breast Cancer are closed or at capacity right now (read 2026-11-08).
Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Metastatic Breast Cancer
- Closed or at capacityMetastatic Breast Cancer
CancerCare ·
Award level: not statedInsurance supported: not stated
The page marks the fund as not currently open for new enrollments (the fund row's own data-statuses attribute reads closed). Source page
- Closed or at capacityMetastatic Breast Cancer
Good Days ·
Award level: not statedInsurance supported: not stated
The page marks the fund as not currently open for new enrollments (the fund's list item on the page carries the class closed). Source page
- Closed or at capacityMetastatic breast cancer
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $7,000Insurance supported: Any health insurance
The page lists the fund as Closed. Source page
Drugs whose FDA label names Metastatic Breast Cancer
8 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 6 have a program (in our assistance finder or on the program's own page) and 1 has a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Verzenio Abemaciclib Every route for this drug | ... an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Label on openFDA, read 2026-11-10 | Lilly Cares | selected by CMS for 2028; price not yet published |
| Ibrance Palbociclib Every route for this drug | ... for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1. Label on openFDA, read 2026-11-10 | Pfizer RxPathways Limited Cancer Drug Assistance (Multiple Programs) | $7,871.00 for a 30-day supply, effective 2027-01-01 |
| Kisqali Ribociclib Every route for this drug | ... for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; Label on openFDA, read 2026-11-10 | Novartis Patient Assistance Foundation (NPAF) (program page) | selected by CMS for 2028; price not yet published |
| Piqray Alpelisib Every route for this drug | ... hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. Label on openFDA, read 2026-11-10 | Novartis Patient Assistance Foundation (NPAF) (program page) | not in the CMS negotiated-price file |
| Truqap Capivasertib Every route for this drug | HR positive, HER2 negative locally advanced or metastatic breast cancer • in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally ... Label on openFDA, read 2026-11-10 | AZ&Me Prescription Savings Program Limited | not in the CMS negotiated-price file |
| Lynparza Olaparib Every route for this drug | ... for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Label on openFDA, read 2026-11-10 | Cancer Drug Assistance (Multiple Programs) AZ&Me Prescription Savings Program Limited | not in the CMS negotiated-price file |
| Orserdu Elacestrant Hcl | ... estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test [see Dosage and Administration ( 2. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
| Tukysa Tucatinib | Metastatic Breast Cancer TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer ... Label on openFDA, read 2026-11-10 | Pfizer RxPathways (Pfizer Patient Assistance Program) Not in its current list The program's page printed this drug in an earlier list and not in its current one. | not in the CMS negotiated-price file |
Funds for costs around Metastatic Breast Cancer
These pay for a kind of cost, not a diagnosis. Each is shown with its own status.
Funds for costs around cancer and blood cancer in general: behavioral health (1 open of 2), caregiver support (0 open of 2), clinical trial costs (0 open of 1), home care (1 open of 1), named fund (0 open of 1), pain management (0 open of 1), testing (1 open of 1) and transportation (0 open of 1). Every one is listed, with its source, on the Cancer and blood cancer page.
Related conditions
Group: Cancer and blood cancer. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: metastatic-breast-cancer.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Metastatic Breast Cancer?
As read on 2026-11-08, none of the 3 funds we hold for Metastatic Breast Cancer say they are open. Funds reopen, so use the alert on this page.
Which organizations run funds for Metastatic Breast Cancer?
CancerCare, Good Days and TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.